DE60027691D1 - Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5-fluorocytidin für die verwendung in der behandlung von hiv infektionen - Google Patents

Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5-fluorocytidin für die verwendung in der behandlung von hiv infektionen

Info

Publication number
DE60027691D1
DE60027691D1 DE60027691T DE60027691T DE60027691D1 DE 60027691 D1 DE60027691 D1 DE 60027691D1 DE 60027691 T DE60027691 T DE 60027691T DE 60027691 T DE60027691 T DE 60027691T DE 60027691 D1 DE60027691 D1 DE 60027691D1
Authority
DE
Germany
Prior art keywords
beta
d4fc
hiv
didesoxy
fluorocytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027691T
Other languages
English (en)
Other versions
DE60027691T2 (de
Inventor
Raymond F Schinazi
Jennifer Hammond
John W Mellors
Dennis C Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of DE60027691D1 publication Critical patent/DE60027691D1/de
Application granted granted Critical
Publication of DE60027691T2 publication Critical patent/DE60027691T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60027691T 1999-01-22 2000-01-21 Beta-D-2',3'-didehydro-2',3'-didesoxy-5-fluorcytidin für die Verwendung in der Behandlung von HIV Infektionen Expired - Lifetime DE60027691T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22
US116773P 1999-01-22
PCT/US2000/001738 WO2000043014A2 (en) 1999-01-22 2000-01-21 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Publications (2)

Publication Number Publication Date
DE60027691D1 true DE60027691D1 (de) 2006-06-08
DE60027691T2 DE60027691T2 (de) 2007-04-12

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027691T Expired - Lifetime DE60027691T2 (de) 1999-01-22 2000-01-21 Beta-D-2',3'-didehydro-2',3'-didesoxy-5-fluorcytidin für die Verwendung in der Behandlung von HIV Infektionen

Country Status (21)

Country Link
EP (1) EP1143976B9 (de)
JP (1) JP2002535278A (de)
KR (1) KR100745408B1 (de)
CN (2) CN1337880A (de)
AT (1) ATE324894T1 (de)
AU (1) AU781281B2 (de)
BR (1) BR0007627A (de)
CA (1) CA2360039C (de)
DE (1) DE60027691T2 (de)
DK (1) DK1143976T3 (de)
ES (1) ES2263449T3 (de)
HK (1) HK1040064B (de)
IL (1) IL144382A (de)
MX (1) MXPA01007359A (de)
NO (1) NO323586B1 (de)
NZ (1) NZ528156A (de)
PL (1) PL198237B1 (de)
PT (1) PT1143976E (de)
RU (1) RU2254133C2 (de)
WO (1) WO2000043014A2 (de)
ZA (1) ZA200105971B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536800B1 (de) * 2002-06-27 2006-01-04 Medivir Ab Synergistische wechselwirkung von abacavir und alovudin
EP1694300A4 (de) * 2003-12-09 2009-04-29 Pharmasset Inc Dosierverfahren für beta-d-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidin-anitvirale therapie
WO2005097618A2 (en) 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
EP1802315A2 (de) * 2004-10-19 2007-07-04 Achillion Pharmaceuticals, Inc. Kombinationstherapie zur behandlung von virusinfektionen
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol

Also Published As

Publication number Publication date
PL198237B1 (pl) 2008-06-30
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
NO20013599L (no) 2001-09-20
WO2000043014A8 (en) 2001-01-18
ES2263449T3 (es) 2006-12-16
RU2254133C2 (ru) 2005-06-20
NO20013599D0 (no) 2001-07-20
WO2000043014A2 (en) 2000-07-27
EP1143976A2 (de) 2001-10-17
WO2000043014A3 (en) 2000-11-30
CN1337880A (zh) 2002-02-27
PT1143976E (pt) 2006-09-29
EP1143976B1 (de) 2006-05-03
ATE324894T1 (de) 2006-06-15
DE60027691T2 (de) 2007-04-12
CN101219148A (zh) 2008-07-16
CA2360039A1 (en) 2000-07-27
AU2627000A (en) 2000-08-07
KR100745408B1 (ko) 2007-08-02
EP1143976B9 (de) 2007-02-14
HK1040064B (zh) 2006-07-21
NZ528156A (en) 2005-03-24
IL144382A0 (en) 2002-05-23
ZA200105971B (en) 2002-10-21
DK1143976T3 (da) 2006-09-04
IL144382A (en) 2007-02-11
JP2002535278A (ja) 2002-10-22
BR0007627A (pt) 2002-04-09
AU781281B2 (en) 2005-05-12
HK1040064A1 (en) 2002-05-24
CA2360039C (en) 2009-11-24
MXPA01007359A (es) 2003-09-22

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
DE69939705D1 (de) Behandlung der pompeschen krankheit
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE324894T1 (de) Beta-d-2', 3' -didehydro-2', 3' -didesoxy-5- fluorocytidin für die verwendung in der behandlung von hiv infektionen
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE69328667T2 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
EP1731155A3 (de) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine für die verwendung in der behandlung von hiv infektionen
DE60025826D1 (de) Pyrazolidinol-verbindungen
KR890001555A (ko) 요산 배설용 조성물
HUP0105469A2 (hu) Pirroloazepineket tartalmazó gyógyászati készítmények claudicatio intermittens kezelésére
RU2000104538A (ru) Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита
James PMPA--first human results
TH45970A (th) การบำบัดรักษา hiv ด้วยการใช้ยาร่วมกันของพีกีเลท อินเตอร์ฟิรอนอัลฟา-ตัวต่อต้าน ccr5
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
HUP9801545A2 (hu) 2-Metil-4-amino-izotiazolin-3-on-származékok, cisztindiamidok és eljárás ezek előállítására, valamint e vegyületek alkalmazása
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition